172 related articles for article (PubMed ID: 31754048)
1. Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial.
Hiller JG; Cole SW; Crone EM; Byrne DJ; Shackleford DM; Pang JB; Henderson MA; Nightingale SS; Ho KM; Myles PS; Fox S; Riedel B; Sloan EK
Clin Cancer Res; 2020 Apr; 26(8):1803-1811. PubMed ID: 31754048
[TBL] [Abstract][Full Text] [Related]
2. Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial.
Shaashua L; Shabat-Simon M; Haldar R; Matzner P; Zmora O; Shabtai M; Sharon E; Allweis T; Barshack I; Hayman L; Arevalo J; Ma J; Horowitz M; Cole S; Ben-Eliyahu S
Clin Cancer Res; 2017 Aug; 23(16):4651-4661. PubMed ID: 28490464
[No Abstract] [Full Text] [Related]
3. Perioperative COX2 and β-adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial.
Haldar R; Ricon-Becker I; Radin A; Gutman M; Cole SW; Zmora O; Ben-Eliyahu S
Cancer; 2020 Sep; 126(17):3991-4001. PubMed ID: 32533792
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade.
Choy C; Raytis JL; Smith DD; Duenas M; Neman J; Jandial R; Lew MW
Oncol Rep; 2016 Jun; 35(6):3135-42. PubMed ID: 27035124
[TBL] [Abstract][Full Text] [Related]
5. Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?
Blaes AH; Domingo-Musibay E; Kalinsky K
Clin Cancer Res; 2020 Apr; 26(8):1781-1783. PubMed ID: 32029438
[TBL] [Abstract][Full Text] [Related]
6. Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.
Montoya A; Amaya CN; Belmont A; Diab N; Trevino R; Villanueva G; Rains S; Sanchez LA; Badri N; Otoukesh S; Khammanivong A; Liss D; Baca ST; Aguilera RJ; Dickerson EB; Torabi A; Dwivedi AK; Abbas A; Chambers K; Bryan BA; Nahleh Z
Oncotarget; 2017 Jan; 8(4):6446-6460. PubMed ID: 28031536
[TBL] [Abstract][Full Text] [Related]
7. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
de Groot AF; Blok EJ; Charehbili A; Engels CC; Smit VTHBM; Dekker-Ensink NG; Putter H; Meershoek-Klein Kranenbarg E; van de Velde CJH; Liefers GJ; Nortier JWR; Kuppen PJK; van der Burg SH; Kroep JR
Breast Cancer Res Treat; 2019 Jun; 175(3):605-615. PubMed ID: 30868392
[TBL] [Abstract][Full Text] [Related]
8. Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.
Haldar R; Shaashua L; Lavon H; Lyons YA; Zmora O; Sharon E; Birnbaum Y; Allweis T; Sood AK; Barshack I; Cole S; Ben-Eliyahu S
Brain Behav Immun; 2018 Oct; 73():294-309. PubMed ID: 29800703
[TBL] [Abstract][Full Text] [Related]
9. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.
Knight JM; Rizzo JD; Hari P; Pasquini MC; Giles KE; D'Souza A; Logan BR; Hamadani M; Chhabra S; Dhakal B; Shah N; Sriram D; Horowitz MM; Cole SW
Blood Adv; 2020 Feb; 4(3):467-476. PubMed ID: 32027744
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
Coleman R; Finkelstein DM; Barrios C; Martin M; Iwata H; Hegg R; Glaspy J; Periañez AM; Tonkin K; Deleu I; Sohn J; Crown J; Delaloge S; Dai T; Zhou Y; Jandial D; Chan A
Lancet Oncol; 2020 Jan; 21(1):60-72. PubMed ID: 31806543
[TBL] [Abstract][Full Text] [Related]
12. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
[TBL] [Abstract][Full Text] [Related]
13. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
15. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
16. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
18. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
[TBL] [Abstract][Full Text] [Related]
20. The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer.
Montoya A; Varela-Ramirez A; Dickerson E; Pasquier E; Torabi A; Aguilera R; Nahleh Z; Bryan B
Biomed J; 2019 Jun; 42(3):155-165. PubMed ID: 31466709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
